PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Methotrexate - Rheumatology indications

PAD Profile : Methotrexate - Rheumatology indications Important

Keywords :
Shared Care, thiopurine, RA, shared care, active rheumatoid arthritis, severe psoriatic arthritis, inflammatory arthritis, connective tissue disease, vasculitis
Important Information :
WEEKLY dosing.

Traffic Light Status

Status 1 of 2.

Status :
Amber
Formulations :
  • Injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Amber
Important
Formulations :
  • Tablets
Important Information :
2.5mg tablets ONLY. DO NOT PRESCRIBE OR SUPPLY 10mg tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
SA
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
02 August 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a local adaptation of the National Shared Care document, in reference to the routine monitoring of CRP (rather than ESR) in primary care for inflammatory indications

02 November 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve the RMOC national shared care protocol with ‘local adaptations’.

This shared care protocol applies to adults aged 18 and over.

This shared care protocol also includes treatment of chronic inflammatory conditions where off-label use of methotrexate is appropriate, including, but not limited to, the specialities and conditions described in Section 3 of the document.

These indications are off-label. The specialist must specify the indication for each patient when initiating shared care and clearly state when use is off-label (refer to section 3 for further information).

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More